<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00125645</url>
  </required_header>
  <id_info>
    <org_study_id>VF 20040053</org_study_id>
    <secondary_id>2612</secondary_id>
    <nct_id>NCT00125645</nct_id>
  </id_info>
  <brief_title>Left Ventricular Function After Acute Myocardial Infarction (AMI). Treatment With Angiotensin 2-Receptor Blockade (GLOBAL-Study)</brief_title>
  <official_title>Global Left Ventricular Function After Acute Myocardial Infarction. Treatment With the Angiotensin 2-Receptor Blocker Irbesartan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern Denmark</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare changes in global left ventricular (LV) function&#xD;
      after 3 months of treatment with irbesartan compared with usual care in patients with acute&#xD;
      myocardial infarction, a wall motion score &gt;1.3 (EF&gt;0.40) and signs of diastolic dysfunction.&#xD;
      The hypothesis is that an angiotensin 2-receptor inhibitor will improve global left&#xD;
      ventricular function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study objectives:&#xD;
&#xD;
      Primary Objective:&#xD;
&#xD;
      To compare the change in global LV function assessed with myocardial performance index (MPI)&#xD;
      after 3 months treatment with irbesartan compared to usual care in patients admitted to&#xD;
      hospital with acute myocardial infarction, wall motion score index &gt; 1.3 (LVEF &gt; 0.40), and&#xD;
      MPI &gt; 0.55.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To compare irbesartan added to an ACE-inhibitor compared to usual care in patients with&#xD;
           AMI, WMSI &lt;= 1.3 and MPI &gt; 0.55;&#xD;
&#xD;
        -  To compare LV diastolic function assessed by pulse wave and color M-mode Doppler&#xD;
           echocardiography and left atrial size after treatment with irbesartan compared to usual&#xD;
           care in AMI and&#xD;
&#xD;
             -  WMSI &gt; 1.3 and MPI &gt; 0.55; and&#xD;
&#xD;
             -  WMSI &lt;= 1.3 and MPI &gt; 0.55.&#xD;
&#xD;
        -  To compare change in WMSI after treatment with irbesartan compared to usual care in&#xD;
           patients with AMI and&#xD;
&#xD;
             -  WMSI &gt; 1.3 and MPI &gt; 0.55; and&#xD;
&#xD;
             -  WMSI &lt;= 1.3 and MPI &gt; 0.55.&#xD;
&#xD;
      Tertiary Objectives:&#xD;
&#xD;
      To assess the effects of irbesartan versus usual care on neurohormonal activation and glucose&#xD;
      metabolism (optional).&#xD;
&#xD;
      Study Design:&#xD;
&#xD;
      A Danish multicenter randomized prospective trial with PROBE-design.&#xD;
&#xD;
      Study Drug:&#xD;
&#xD;
      Patients will be randomized to receive either: irbesartan 300 mg once daily or usual care.&#xD;
&#xD;
      Duration of Therapy:&#xD;
&#xD;
      Irbesartan 300 mg daily for 3 months after hospital discharge for acute myocardial&#xD;
      infarction.&#xD;
&#xD;
      Patients should receive standard medical therapy including revascularisation as appropriate.&#xD;
&#xD;
      Expected Number of Patients:&#xD;
&#xD;
      200 patients with AMI, WMSI &gt; 1.3 and MPI &gt; 0.55 (100 patients in the irbesartan group and&#xD;
      100 in the usual care group). The patients will be included in the analysis of the primary&#xD;
      endpoint. Further, approximately 100 patients with AMI, WMSI &lt;= 1.3 and MPI &gt; 0.55 treated&#xD;
      with an ACE-inhibitor would be part of the secondary endpoints.&#xD;
&#xD;
      Main Inclusion Criteria:&#xD;
&#xD;
        -  Patients admitted to hospital with clinical symptoms of acute myocardial infarction&#xD;
           and/or electrocardiographic signs of AMI and a documented elevation in cardiac markers&#xD;
           (troponin T or I) or elevation of cardiac enzymes (creatinine kinase MB).&#xD;
&#xD;
        -  Myocardial performance index (MPI) &gt; 0.55 determined by echocardiography prior to&#xD;
           randomization.&#xD;
&#xD;
        -  Be randomized within 7 days of AMI (in or out patient).&#xD;
&#xD;
        -  Written informed consent&#xD;
&#xD;
      Main Exclusion Criteria:&#xD;
&#xD;
        -  Age &lt; 18 years.&#xD;
&#xD;
        -  Any contraindications to angiotensin 2-receptor blocker.&#xD;
&#xD;
        -  In patients with WMSI &gt; 1.3 treatment with ACE-inhibitor or angiotensin 2-receptor&#xD;
           blockers.&#xD;
&#xD;
        -  In patients with WMSI &lt;= 1.3 no initiated or planned treatment with an ACE-inhibitor.&#xD;
           Treatment with an ACE-inhibitor must be started within 7 days.&#xD;
&#xD;
        -  Pregnancy or women of childbearing potential who are not using an effective method of&#xD;
           contraception.&#xD;
&#xD;
        -  Other comorbid conditions that would influence the study.&#xD;
&#xD;
        -  Currently receiving an experimental study-drug.&#xD;
&#xD;
      Study Medication:&#xD;
&#xD;
      Irbesartan 300 mg once daily which can be reduced to 150 mg at the discretion of the treating&#xD;
      physician. With a dose less than 150 mg patients will be excluded from analysis.&#xD;
&#xD;
      Mode of Administration:&#xD;
&#xD;
      The drugs will be given unblinded, but with blinded assessment of the endpoints.&#xD;
&#xD;
      Evaluation Criteria:&#xD;
&#xD;
      Primary Outcome:&#xD;
&#xD;
      Change in MPI in patients with WMSI &gt; 1.3 treated with either irbesartan or usual care.&#xD;
&#xD;
      Secondary Outcomes:&#xD;
&#xD;
        -  Change in MPI in patients with WMSI &lt;= 1.3 on an ACE-inhibitor treated with either&#xD;
           irbesartan or usual care.&#xD;
&#xD;
        -  Change in left ventricular diastolic function (pulse wave and color M-mode&#xD;
           echocardiography and left atrial size) in patients with WMSI &gt; 1.3 or &lt;= 1.3.&#xD;
&#xD;
        -  Change in LV systolic function (WMSI and LVEF) in patients with WMSI &gt; 1.3 or WMSI &lt;=&#xD;
           1.3.&#xD;
&#xD;
      Tertiary Outcomes:&#xD;
&#xD;
      Changes in neurohormonal activation and glucose metabolism (optional).&#xD;
&#xD;
      Definitions of Objectives:&#xD;
&#xD;
      Myocardial Performance Index:&#xD;
&#xD;
      MPI is calculated as the sum of the isovolumetric relaxation and contraction times divided by&#xD;
      ejection time; this is measured from mitral inflow and left ventricular outflow recording&#xD;
      obtained by pulse wave Doppler echocardiography.&#xD;
&#xD;
      LV Diastolic Function:&#xD;
&#xD;
        -  Assessment of mitral inflow curve, E- and A-wave and deceleration time of the E-wave.&#xD;
&#xD;
        -  Color M-mode:&#xD;
&#xD;
      Assessment of the flow propagation velocity.&#xD;
&#xD;
        -  Left atrial size measured by single plane volume in a four chamber view.&#xD;
&#xD;
      Systolic Function:&#xD;
&#xD;
        -  Wall motion score index: LV is divided into 16 segments which are scored based on&#xD;
           myocardial thickening and endocardial excursion (3 = hyperkinesis, 2 = normokinesis, 1 =&#xD;
           hypokinesis, 0 = akinesis and -1 = paradoxical motion). WMSI is calculated by dividing&#xD;
           the sum of scores by the number of segments analyzed.&#xD;
&#xD;
        -  LV ejection fraction is obtained by multiplying WMSI by 30.&#xD;
&#xD;
      Neurohormonal activation is assessed by pro-NT-BNP and glycemic control is assessed by an&#xD;
      oral glucose tolerance test during hospitalisation and after 3 months in patients without&#xD;
      known diabetes mellitus (optional).&#xD;
&#xD;
      Statistical Considerations:&#xD;
&#xD;
      Population Analyzed: All randomized patients will be in the study for the planned treatment&#xD;
      period of 3 months, but only patients on &gt;= 150 mg irbesartan will be analyzed according to&#xD;
      the primary endpoint.&#xD;
&#xD;
      Sample Size Consideration: The primary study objective is to show that irbesartan will&#xD;
      improve MPI more than usual care after 3 months treatment in patients with AMI, WMSI &gt; 1.3&#xD;
      and MPI &gt; 0.55.&#xD;
&#xD;
      Furthermore, patients with reduced LV function (WMSI &lt;= 1.3) and with reduced global LV&#xD;
      function (MPI &gt; 0.55) will be included in the study and irbesartan will be added to an&#xD;
      ACE-inhibitor compared to usual care. This patient will be included in the secondary&#xD;
      objectives and therefore no sample size estimation has been performed. 100 patients are&#xD;
      estimated to be enrolled in this study group and will be used for descriptive purposes.&#xD;
&#xD;
      It is assumed that MPI has a normal distribution in the study population and from previous&#xD;
      populations of patients with AMI it is found, that MPIs have a mean value of 0.55 (SD 0.20)&#xD;
      in patients with WMSI &gt; 1.3; based on an estimated change in MPI of 20% in the irbesartan&#xD;
      group a total of approximately 200 patients are needed for the study.&#xD;
&#xD;
      Duration of Treatment and Observations:&#xD;
&#xD;
      Treatment:&#xD;
&#xD;
      Patients will receive irbesartan 300 mg daily (at least 150 mg per day) for 3 months&#xD;
      treatment.&#xD;
&#xD;
      The primary observation period will be 3 months corresponding to the treatment period, but&#xD;
      vital status or hospitalisation will be noted after 6 and 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2005</start_date>
  <completion_date type="Actual">September 1, 2011</completion_date>
  <primary_completion_date type="Actual">September 1, 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Comparison with EF</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular function</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Irbesartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet Irbesartan 150 mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irbesartan Oral Tablet</intervention_name>
    <arm_group_label>Irbesartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented AMI; MPI &gt; 0.55&#xD;
&#xD;
          -  Randomized within 7 days of AMI&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Any contraindications to angiotensin 2-receptor blockade&#xD;
&#xD;
          -  In patients with WMSI &gt; 1.3 treatment with ACE-inhibitor or angiotensin 2-receptor&#xD;
             blockers&#xD;
&#xD;
          -  In patients with WMSI &lt;= 1.3 no initiated or planned treatment with an ACE-inhibitor.&#xD;
             Treatment with an ACE-inhibitor must be started within 7 days&#xD;
&#xD;
          -  Pregnancy or women of childbearing potential who are not using an effective method of&#xD;
             contraception&#xD;
&#xD;
          -  Other comorbid conditions that could influence the study&#xD;
&#xD;
          -  Currently receiving an experimental study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Egstrup, Asst. Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Medical Research, SHF Svendborg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kardiologisk Klinik, Centralsygehuset Esbjerg/Varde</name>
      <address>
        <city>Esbjerg</city>
        <zip>6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>July 29, 2005</study_first_submitted>
  <study_first_submitted_qc>July 29, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2005</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern Denmark</investigator_affiliation>
    <investigator_full_name>Kenneth Egstrup</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>AMI</keyword>
  <keyword>Left ventricular function</keyword>
  <keyword>Myocardial performance index</keyword>
  <keyword>Acute myocardial infarction (AMI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irbesartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

